Literature DB >> 2442679

Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain.

G P Reynolds, S J Pearson.   

Abstract

gamma-Aminobutyric acid (GABA), glutamate and serotonin (5-HT), along with its major metabolite, 5-hydroxyindoleacetic acid (5-HIAA), have been measured in 4 brain regions taken post-mortem from patients with Huntington's disease and from control subjects. GABA was found to be significantly reduced, not only in the basal ganglia, but also in the cortex and hippocampus. Glutamate was also reduced in all regions except the pallidum, and thus was unrelated to the GABA deficit which was greatest in this area. 5-HT and 5-HIAA were significantly increased in all areas except the hippocampus.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2442679     DOI: 10.1016/0304-3940(87)90639-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  16 in total

1.  Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.

Authors:  Wenzhen Duan; Qi Peng; Naoki Masuda; Eric Ford; Erik Tryggestad; Bruce Ladenheim; Ming Zhao; Jean Lud Cadet; John Wong; Christopher A Ross
Journal:  Neurobiol Dis       Date:  2008-03-10       Impact factor: 5.996

Review 2.  Huntington's disease: the coming of age.

Authors:  Mritunjay Pandey; Usha Rajamma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

3.  EGF Treatment Improves Motor Behavior and Cortical GABAergic Function in the R6/2 Mouse Model of Huntington's Disease.

Authors:  Felecia M Marottoli; Mercedes Priego; Eden Flores-Barrera; Rohan Pisharody; Steve Zaldua; Kelly D Fan; Giri K Ekkurthi; Scott T Brady; Gerardo A Morfini; Kuei Y Tseng; Leon M Tai
Journal:  Mol Neurobiol       Date:  2019-05-19       Impact factor: 5.590

4.  Neurochemical correlates of caudate atrophy in Huntington's disease.

Authors:  Jeannie M Padowski; Kurt E Weaver; Todd L Richards; Mercy Y Laurino; Ali Samii; Elizabeth H Aylward; Kevin E Conley
Journal:  Mov Disord       Date:  2014-01-17       Impact factor: 10.338

5.  Neocortical neurotransmitter markers in Huntington's disease.

Authors:  S J Pearson; G P Reynolds
Journal:  J Neural Transm Gen Sect       Date:  1994

6.  Effects of NMDA receptor antagonists on passive avoidance learning and retrieval in rats and mice.

Authors:  N Venable; P H Kelly
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Creatine supplementation lowers brain glutamate levels in Huntington's disease.

Authors:  Andreas Bender; Dorothee P Auer; Thomas Merl; Ralf Reilmann; Phillip Saemann; Alexander Yassouridis; Julia Bender; Adolf Weindl; Matthias Dose; Thomas Gasser; Thomas Klopstock
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

8.  The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy.

Authors:  D M Mann; R Oliver; J S Snowden
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.

Authors:  Qi Peng; Naoki Masuda; Mali Jiang; Qing Li; Ming Zhao; Christopher A Ross; Wenzhen Duan
Journal:  Exp Neurol       Date:  2007-11-09       Impact factor: 5.330

10.  Cortical and striatal neurone number in Huntington's disease.

Authors:  H Heinsen; M Strik; M Bauer; K Luther; G Ulmar; D Gangnus; G Jungkunz; W Eisenmenger; M Götz
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.